Commission authorises medicine to treat postpartum depression
The European Commission has granted EU marketing authorisation for zuranolone, a medicine to treat postpartum depression (PPD). PPD is a mental health condition that can affect women following childbirth and is marked by persistent sadness, anxiety, fatigue and difficulty functioning. It can be severe and long-lasting, with negative consequences for the mother and child. There …